Nilesh Shah joins Illumina as Head of Region, AMEA

19.08.25 08:14 Uhr

Werte in diesem Artikel
Aktien

85,93 EUR -0,44 EUR -0,51%

SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately.

Nilesh Shah, Head of Region, AMEA, Illumina (PRNewsfoto/Illumina)

Nilesh brings over 25 years of leadership experience in the medical technology and life sciences industries, having held senior roles at Johnson & Johnson, GE Healthcare and most recently, West Pharmaceutical Services. At West, he served as Vice President & General Manager, Emerging Markets, where he led commercial, operational, and manufacturing strategies spanning Asia-Pacific and Latin America. During his tenure, he drove regional transformation, enhanced customer engagement, and delivered strong growth through a more aligned and agile operating model.

"We are excited to welcome Nilesh to Illumina. His deep expertise in healthcare and global organizations is a valuable addition to the AMEA team and our broader commercial organization," said Everett Cunningham, Chief Commercial Officer at Illumina. "AMEA represents one of the most dynamic and fast-growing regions in the world, with significant opportunities to expand access to genomic technologies. We look forward to seeing how Nilesh's leadership will help shape the next chapter of growth and impact across the region."

"Genomics and multi-omics are rapidly transforming precision medicine and reshaping healthcare across every stage of life," Nilesh stated. "I am honored to join Illumina as Head of AMEA. Together, we will work with our customers, partners, and the entire ecosystem to harness the full potential of these technologies – not just advancing regional health outcomes, but improving health for communities worldwide."

Nilesh will be based in Singapore. He succeeds Bas Verhoef, interim Head of Region, AMEA. Verhoef will continue to serve as Head of Region for Europe. 

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on XFacebookLinkedInInstagramTikTok, and YouTube.

(PRNewsfoto/Illumina)

Cision View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/nilesh-shah-joins-illumina-as-head-of-region-amea-302533180.html

SOURCE Illumina

In eigener Sache

Übrigens: Illumina und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Illumina

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Illumina

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Illumina Inc.

Wer­bung

Analysen zu Illumina Inc.

DatumRatingAnalyst
30.07.2019Illumina HoldCanaccord Adams
30.05.2019Illumina OutperformWolfe Research
09.10.2018Illumina NeutralUBS AG
31.07.2018Illumina BuyCanaccord Adams
31.01.2018Illumina OverweightFirst Analysis Securities
DatumRatingAnalyst
30.05.2019Illumina OutperformWolfe Research
31.07.2018Illumina BuyCanaccord Adams
31.01.2018Illumina OverweightFirst Analysis Securities
25.10.2017Illumina OutperformRobert W. Baird & Co. Incorporated
23.10.2017Illumina BuyDeutsche Bank AG
DatumRatingAnalyst
30.07.2019Illumina HoldCanaccord Adams
09.10.2018Illumina NeutralUBS AG
05.01.2018Illumina NeutralBTIG Research
02.08.2017Illumina Equal-WeightFirst Analysis Securities
26.04.2017Illumina NeutralCantor Fitzgerald
DatumRatingAnalyst
02.11.2016Illumina UnderweightFirst Analysis Securities

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Illumina Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen